Evaluation of the role of unconventional prefoldin RPB5 interactor (URI1) in hepatitis B virus infection
Abstract Hepatitis B virus (HBV) infection can cause liver disease and lead to hepatocellular carcinoma (HCC). To better understand the factors involved in viral infection and pathogenesis and to develop novel therapies, it is crucial to investigate virus–host interactions. HBV infection has been sh...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Virology Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12985-024-02617-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544999905263616 |
|---|---|
| author | Karolína Štaflová Aleš Zábranský Iva Pichová |
| author_facet | Karolína Štaflová Aleš Zábranský Iva Pichová |
| author_sort | Karolína Štaflová |
| collection | DOAJ |
| description | Abstract Hepatitis B virus (HBV) infection can cause liver disease and lead to hepatocellular carcinoma (HCC). To better understand the factors involved in viral infection and pathogenesis and to develop novel therapies, it is crucial to investigate virus–host interactions. HBV infection has been shown to increase the expression of the unconventional prefoldin RPB5 interactor (URI1), a cellular protein that promotes liver tumorigenesis and HCC metastasis. Our study investigated the role of URI1 in HBV infection in vitro. Although previous reports have suggested that URI1 may act as an HBV restriction factor, our results showed that URI1 silencing or overexpression did not affect HBV replication in HepG2-NTCP cells. In primary human hepatocytes, URI1 knockdown modestly reduced HBV markers but did not significantly alter acute infection. Supporting the premise that URI1 is a promising therapeutic target for HCC, our findings show that URI1 knockdown does not enhance HBV infection in an acute infection model. This suggests that URI1 may be a viable therapeutic target for patients with HBV-associated HCC without increasing HBV-related complications. |
| format | Article |
| id | doaj-art-c2b0222be9eb48e78f84134d1650a861 |
| institution | Kabale University |
| issn | 1743-422X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Virology Journal |
| spelling | doaj-art-c2b0222be9eb48e78f84134d1650a8612025-01-12T12:08:09ZengBMCVirology Journal1743-422X2025-01-012211810.1186/s12985-024-02617-2Evaluation of the role of unconventional prefoldin RPB5 interactor (URI1) in hepatitis B virus infectionKarolína Štaflová0Aleš Zábranský1Iva Pichová2Institute of Organic Chemistry and Biochemistry, Czech Academy of SciencesInstitute of Organic Chemistry and Biochemistry, Czech Academy of SciencesInstitute of Organic Chemistry and Biochemistry, Czech Academy of SciencesAbstract Hepatitis B virus (HBV) infection can cause liver disease and lead to hepatocellular carcinoma (HCC). To better understand the factors involved in viral infection and pathogenesis and to develop novel therapies, it is crucial to investigate virus–host interactions. HBV infection has been shown to increase the expression of the unconventional prefoldin RPB5 interactor (URI1), a cellular protein that promotes liver tumorigenesis and HCC metastasis. Our study investigated the role of URI1 in HBV infection in vitro. Although previous reports have suggested that URI1 may act as an HBV restriction factor, our results showed that URI1 silencing or overexpression did not affect HBV replication in HepG2-NTCP cells. In primary human hepatocytes, URI1 knockdown modestly reduced HBV markers but did not significantly alter acute infection. Supporting the premise that URI1 is a promising therapeutic target for HCC, our findings show that URI1 knockdown does not enhance HBV infection in an acute infection model. This suggests that URI1 may be a viable therapeutic target for patients with HBV-associated HCC without increasing HBV-related complications.https://doi.org/10.1186/s12985-024-02617-2Unconventional prefoldin RPB5 interactorURI1Hepatitis B virusHBVHepatocellular carcinoma |
| spellingShingle | Karolína Štaflová Aleš Zábranský Iva Pichová Evaluation of the role of unconventional prefoldin RPB5 interactor (URI1) in hepatitis B virus infection Virology Journal Unconventional prefoldin RPB5 interactor URI1 Hepatitis B virus HBV Hepatocellular carcinoma |
| title | Evaluation of the role of unconventional prefoldin RPB5 interactor (URI1) in hepatitis B virus infection |
| title_full | Evaluation of the role of unconventional prefoldin RPB5 interactor (URI1) in hepatitis B virus infection |
| title_fullStr | Evaluation of the role of unconventional prefoldin RPB5 interactor (URI1) in hepatitis B virus infection |
| title_full_unstemmed | Evaluation of the role of unconventional prefoldin RPB5 interactor (URI1) in hepatitis B virus infection |
| title_short | Evaluation of the role of unconventional prefoldin RPB5 interactor (URI1) in hepatitis B virus infection |
| title_sort | evaluation of the role of unconventional prefoldin rpb5 interactor uri1 in hepatitis b virus infection |
| topic | Unconventional prefoldin RPB5 interactor URI1 Hepatitis B virus HBV Hepatocellular carcinoma |
| url | https://doi.org/10.1186/s12985-024-02617-2 |
| work_keys_str_mv | AT karolinastaflova evaluationoftheroleofunconventionalprefoldinrpb5interactoruri1inhepatitisbvirusinfection AT aleszabransky evaluationoftheroleofunconventionalprefoldinrpb5interactoruri1inhepatitisbvirusinfection AT ivapichova evaluationoftheroleofunconventionalprefoldinrpb5interactoruri1inhepatitisbvirusinfection |